Core Viewpoint - Coherus Oncology, Inc. has announced a proposed underwritten public offering of its common stock to support the commercialization of its product LOQTORZI and fund ongoing clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The proposed offering includes a 30-day option for underwriters to purchase up to 15% additional shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the commercialization of LOQTORZI, continued clinical development of product candidates, and general corporate purposes [2]. Group 3: Company Overview - Coherus Oncology is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes mid-stage clinical candidates targeting various cancers [6]. - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with pipeline candidates and partners [6]. Group 4: Pipeline Information - Coherus' pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses against cancer [7]. - Tagmokitug is in Phase 1b/2a studies for advanced solid tumors, while Casdozokitug is being evaluated in a Phase 2 study for hepatocellular carcinoma [7].

Core Insights - Coherus Oncology, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time, with the presentation accessible via webcast [1] - The webcast will be available for replay until February 13, 2026 [2] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting various cancers [3] - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma (NPC) and advancing new indications for LOQTORZI in combination with its pipeline candidates and partners [3] Pipeline Details - Coherus' oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [4] - Tagmokitug, a selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]

Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) [3] - The company has a pipeline that includes two mid-stage clinical candidates targeting various cancers such as liver, lung, head & neck, and colorectal [3] Upcoming Events - Senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 10:30 a.m. Pacific Time [1] - The presentation and Q&A session will be accessible via webcast, available for replay until February 13, 2026 [1][2] Pipeline and Research - Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses for better cancer treatment outcomes [4] - Tagmokitug, a highly selective cytolytic anti-CCR8 antibody, is currently in Phase 1b/2a studies for advanced solid tumors [4] - Casdozokitug, a novel IL-27 antagonistic antibody, is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma [4]